Objective:
To evaluate the efficacy and safety of VIS-101 in patients with neovascular age-related macular degeneration (nAMD).
Key Findings:
- VIS-101 improved visual acuity with mean gains of >10 letters on the ETDRS scale.
- Central subfield thickness reduced by approximately 100 µm to 150 µm after 3 loading doses.
- About two-thirds of patients required no retreatment at 4 months; about half remained retreatment-free at 6 months.
Interpretation:
VIS-101 demonstrates promising efficacy in improving visual outcomes and reducing retinal thickness in nAMD patients, warranting further investigation.
Limitations:
- Small sample size of 38 patients.
- Short duration of follow-up.
Conclusion:
A phase 2b study is planned for 2026, with potential for a global phase 3 program thereafter, indicating ongoing development of VIS-101 for retinal diseases.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
